Langendonk, M.; Smit, N.A.M.; Plattel, W.; Diepstra, A.; Meerten, T.v.; Visser, L.
Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma. Int. J. Mol. Sci. 2022, 23, 13751.
https://doi.org/10.3390/ijms232213751
AMA Style
Langendonk M, Smit NAM, Plattel W, Diepstra A, Meerten Tv, Visser L.
Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma. International Journal of Molecular Sciences. 2022; 23(22):13751.
https://doi.org/10.3390/ijms232213751
Chicago/Turabian Style
Langendonk, Myra, Nienke A. M. Smit, Wouter Plattel, Arjan Diepstra, Tom van Meerten, and Lydia Visser.
2022. "Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma" International Journal of Molecular Sciences 23, no. 22: 13751.
https://doi.org/10.3390/ijms232213751
APA Style
Langendonk, M., Smit, N. A. M., Plattel, W., Diepstra, A., Meerten, T. v., & Visser, L.
(2022). Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma. International Journal of Molecular Sciences, 23(22), 13751.
https://doi.org/10.3390/ijms232213751